Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

NCT05287347

Pancreatic Adenocarcinoma

WITHDRAWN

Identification of Biomarkers for Early Detection of Pancreatic Cancer

NCT00897494

Pancreatic Cancer

COMPLETED

Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer

NCT00559598

Extrahepatic Bile Duct Cancer Pancreatic Cancer

COMPLETED

Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

NCT02471170

Pancreatic Diseases

ENROLLING_BY_INVITATION

Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery

NCT00900016

Pancreatic Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pancreatic cancer

This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis.
* Patients will have had no prior treatment or surgery

* Subjects will have no prior history of any cancer